Venous thromboembolism prophylaxis in burns

Overview

Burn patients carry substantial risk for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors include prolonged immobilization, central venous catheter placement, hypercoagulability from the systemic inflammatory response, endothelial dysfunction, dehydration, and repeated surgical procedures. Despite this elevated risk, VTE prophylaxis in burns has historically been understudied compared to trauma and general surgical populations, and significant practice variation exists across burn centers.

Wibbenmeyer et al. prospectively screened 148 thermally injured patients with admission and discharge duplex ultrasonography and found a VTE prevalence of 6.1%, with 8 of 9 DVTs being proximal ^[1]. Central venous line placement (p = 0.020) and transfusion of more than 4 units of packed red blood cells (p = 0.023) were independent risk factors. That prevalence is comparable to moderate- to high-risk general surgical patients for whom prophylaxis is already standard of care ^[1]. Ahuja et al. conducted the first prospective randomized controlled study of VTE prophylaxis in burns and found an 8% DVT incidence in the control group versus 0% in the enoxaparin prophylaxis group (p = 0.021), with TBSA, immobility, and length of stay as significant risk factors ^[4]. These foundational studies established the rationale for routine pharmacologic prophylaxis in burn patients.

Pharmacologic Prophylaxis

Enoxaparin Dosing Challenges

Standard enoxaparin dosing results in suboptimal target thromboprophylactic plasma anti-Xa levels in a large proportion of burn patients. A population pharmacokinetic analysis of 408 burn patients (15,517 doses, 1,288 anti-Xa measurements) found that only 56% achieved the target anti-Xa range (0.2-0.4 IU/mL) with equation-based dosing ^[9]. Total burn surface area and body weight significantly influenced clearance and distribution, while glomerular filtration rate had no notable impact. Model-based dosing improved target attainment by more than 70% compared to equation-based dosing, with patients having larger TBSA or higher body weight benefiting most ^[9].

The altered pharmacokinetics in burn patients likely result from several mechanisms: increased extracellular fluid volume during resuscitation increases volume of distribution, augmented renal clearance (common in young burn patients) accelerates drug elimination, and hypoalbuminemia reduces protein binding. These changes are dynamic and evolve over the hospital course, making fixed-dose regimens particularly unreliable.

Higher-Dose Protocols

Implementation of a higher-dose enoxaparin protocol following Western Trauma Association guidelines at a verified burn and trauma center demonstrated improved target attainment ^[8]. Of 196 patients dosed per protocol, 75.5% achieved target peak plasma anti-Xa levels (0.2-0.5 IU/mL), substantially better than historical standard dosing results ^[8]. Burn patients were more likely to achieve target levels than trauma patients (81.1% vs 65.2%, p = 0.016), though an association between severe burns and inability to meet anti-Xa goals was noted ^[8].

Twice-Daily Dosing for Major Burns

A quality improvement study at the Victorian Adult Burns Service implemented enoxaparin 40 mg twice daily (renally and weight adjusted) for adults with burns 20% or greater TBSA ^[11]. Among 138 actively treated patients, VTE complications decreased from 5 cases preguideline (enoxaparin 40 mg daily) to 3 incidental thromboembolisms postguideline. Major bleeding affecting dermal substitute application initially increased from 1 (2%) to 7 cases (15%), but intraoperative tranexamic acid and increased transfusion rates eliminated major bleeding events in the subsequent period. Overall, 88% compliance with the guideline was achieved ^[11].

Risk Stratification

Risk-stratified approaches to prophylaxis are gaining traction. Li et al. applied the Caprini risk assessment model to 1,939 burn center admissions over 3 years and found a 0.67% overall VTE rate ^[5]. Among patients with Caprini scores of 0-2 who received no chemoprophylaxis, only 0.18% developed VTE. The highest-risk group (Caprini score greater than 8) had an 8.82% VTE rate ^[5]. Age, ABSI score, overall and full-thickness TBSA, central venous catheters, delayed ambulation, and length of stay were all significantly associated with VTE occurrence ^[5]. This suggests that a blanket prophylaxis strategy may not be necessary for small burns with early mobilization, but higher-risk patients require aggressive intervention.

Mechanical Prophylaxis

Intermittent Pneumatic Compression

Intermittent pneumatic compression (IPC) devices are the primary mechanical modality for VTE prophylaxis. They reduce DVT risk by augmenting venous return, reducing venous stasis, and stimulating endogenous fibrinolysis. The ACCP guidelines recommend mechanical methods as the primary modality for patients at high bleeding risk (Grade 1A) and as an adjunct to pharmacologic prophylaxis in high-risk surgical patients (Grade 2A) ^[3].

The PREVENT trial, the largest RCT evaluating adjunctive IPC in critically ill patients, randomized 2,003 ICU patients already receiving pharmacologic thromboprophylaxis to IPC or no IPC ^[6]. IPC was applied a median of 22 hours daily for a median of 7 days. Proximal DVT occurred in 3.9% of the IPC group versus 4.2% of controls (relative risk, 0.93; 95% CI, 0.60-1.44; p = 0.74) ^[6]. The trial did not demonstrate additional benefit of IPC when added to pharmacologic prophylaxis in a general ICU population. However, adherence was high and skin complications were low, supporting safety.

A network meta-analysis of 13 RCTs (9,619 critically ill patients) found that LMWH reduced DVT incidence compared to control (OR, 0.59; 95% CrI, 0.33-0.90; high certainty), while compressive devices may reduce DVT risk compared to control but with low-certainty evidence (OR, 0.85; 95% CrI, 0.50-1.50) ^[7]. LMWH was probably more effective than unfractionated heparin (OR, 0.72; 95% CrI, 0.46-0.98; moderate certainty) ^[7].

Practical Application in Burns

In burn patients, IPC serves two primary roles:

1. Sole prophylaxis when pharmacologic agents are contraindicated. This includes the immediate perioperative window (see below), active hemorrhage, recent large excision with concern for graft bleeding, thrombocytopenia (platelets less than 50,000), or heparin-induced thrombocytopenia. In these patients, IPC should be applied to any available extremity. Lower extremity burns or donor sites may preclude standard calf-length devices; thigh-length or foot-pump devices are alternatives.

2. Adjunctive prophylaxis in the highest-risk patients. Patients with large TBSA burns, prolonged immobility, femoral central venous catheters, and multiple risk factors may benefit from combined mechanical and pharmacologic prophylaxis, consistent with ACCP recommendations for high-risk surgical patients ^[2][3].

Compliance is the limiting factor. Devices are frequently removed for dressing changes, physical therapy, and trips to the operating room. Nursing protocols should emphasize reapplication after each interruption.

Perioperative Prophylaxis Management

Hold and Restart Timing

Burn patients undergo frequent operative procedures, often weekly or more during active wound management. Balancing VTE risk against surgical bleeding risk is a daily consideration.

Standard practice for prophylactic enoxaparin is to hold the dose 12 hours before a planned procedure. For patients on twice-daily dosing, the evening dose before a morning case is held. Enoxaparin is restarted 12 to 24 hours postoperatively, provided hemostasis is adequate. Most burn surgeons restart at 12 hours if the operation was limited to debridement or small grafting, and at 24 hours after large excisions or when there is concern about graft adherence.

These intervals derive from general surgical and trauma guidelines, particularly the ACCP recommendations that LMWH be held for at least 12 hours preprocedure ^[3], and from the observation that enoxaparin's anti-Xa activity at prophylactic doses is negligible by 12 hours post-dose. Burn-specific evidence for hold/restart timing does not exist.

Practical Considerations

• Patients going to the OR more than twice weekly may spend a disproportionate amount of time without pharmacologic prophylaxis. For these patients, mechanical prophylaxis becomes essential to maintain some degree of protection during the perioperative gaps.
• Epidural catheters are uncommon in burn surgery but when present require adherence to ASRA guidelines: hold LMWH 12 hours before catheter placement or removal, restart no sooner than 4 hours after catheter manipulation.
• Unfractionated heparin (5,000 units subcutaneous every 8-12 hours) may be preferred in patients with unpredictable OR schedules because of its shorter half-life (hold 4-6 hours preprocedure, restart 2-4 hours postprocedure). However, UFH is less effective than LMWH for DVT prevention in critically ill patients ^[7].

Guidelines

ACCP Guidelines (7th and 8th Editions)

The American College of Chest Physicians guidelines represent the foundational framework for VTE prophylaxis across all patient populations. The 7th edition (2004) recommended that all trauma patients with at least one risk factor receive thromboprophylaxis (Grade 1A), with LMWH as the preferred agent and mechanical methods used when anticoagulants are contraindicated ^[2]. The 8th edition (2008) reinforced these recommendations and added that every hospital should develop a formal VTE prevention strategy (Grade 1A), that mechanical prophylaxis should be used primarily for patients at high bleeding risk (Grade 1A), and that ICU patients should be assessed for VTE risk on admission with most receiving thromboprophylaxis (Grade 1A) ^[3]. Burns were not addressed as a distinct category, which has contributed to the practice variation across burn centers.

Chinese Expert Consensus (2024)

The most comprehensive burn-specific VTE guideline was published in 2024 by the Burn and Trauma Branch of the Chinese Geriatric Medical Association, providing 21 recommendations addressing risk assessment, mechanical prophylaxis, pharmacologic prophylaxis, and management of established VTE in adult burn patients ^[10]. The consensus addressed the heightened risk factors specific to burns and the delicate balance required in anticoagulation therapy to mitigate bleeding risks in patients undergoing repeated surgical procedures ^[10].

Trauma Guidelines

A review of VTE prophylaxis in trauma recommended that most adult major trauma patients should be initiated on mechanical and chemical prophylaxis at admission, with low molecular weight heparin as the standard of care ^[12]. Alternatives including unfractionated heparin, aspirin, and direct oral anticoagulants can be considered in specific populations, and extended duration prophylaxis is indicated in high-risk patients ^[12].

Controversies and Evidence Gaps

No large randomized controlled trial has evaluated VTE prophylaxis regimens head-to-head in a burn-specific population. Ahuja's RCT (n = 100) remains the only prospective randomized trial, and it was underpowered for PE and mortality outcomes ^[4]. The optimal anti-Xa target range for burn patients may differ from trauma patients given the different pathophysiology. The timing of prophylaxis initiation relative to excision and grafting procedures, and the duration of prophylaxis hold for operative procedures, lack evidence-based standardization. The role of direct oral anticoagulants in burn patients has not been studied. Whether mechanical prophylaxis alone is adequate for smaller burns or during the perioperative period is undefined. The interaction between VTE prophylaxis and intraoperative bleeding, particularly during tangential excision, requires further study. Risk assessment models (Caprini, Padua, IMPROVE) perform poorly in critically ill populations already receiving prophylaxis, raising questions about their utility in guiding escalation of therapy ^[5].

References

[1] Wibbenmeyer LA et al. "The prevalence of venous thromboembolism of the lower extremity among thermally injured patients determined by duplex sonography." J Trauma 2003;55(6):1162-7. PMID: 14676666 [2] Geerts WH et al. "Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 2004;126(3 Suppl):338S-400S. PMID: 15383478 [3] Geerts WH et al. "Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)." Chest 2008;133(6 Suppl):381S-453S. PMID: 18574271 [4] Ahuja RB et al. "An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin." Burns 2016;42(8):1693-1698. PMID: 27633687 [5] Li Q et al. "Stratification of venous thromboembolism risk in burn patients by Caprini score." Burns 2019;45(1):140-145. PMID: 30253959 [6] Arabi YM et al. "Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis." N Engl J Med 2019;380(14):1305-1315. PMID: 30779530 [7] Fernando SM et al. "VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis." Chest 2022;161(2):418-428. PMID: 34419428 [8] McKinzie BP et al. "Increased Prophylactic Enoxaparin Dosing Is Associated With Improved Achievement of Target anti-Xa Levels; Implementation of the Western Trauma Association Venous-Thromboembolism Guidelines." J Surg Res 2026;318:300-305. PMID: 41576785 [9] Shenkoya B et al. "A real-world data-driven approach to optimizing enoxaparin dosing in burn patients." Br J Clin Pharmacol 2025;92(4):1126-1136. PMID: 41277282 [10] Zhu F et al. "Chinese expert consensus on prevention, diagnosis, and management of venous thromboembolism in adult burn patients (2024)." Mil Med Res 2025;12(1):74. PMID: 41177896 [11] Sheahan G et al. "Burn-Specific Venous Thromboembolism Prophylaxis: A 2-Year Quality Improvement Project." J Burn Care Res 2026;47(2):590-597. PMID: 41074776 [12] Lippincott M, Berndtson AE. "Prophylaxis of venous thromboembolism in trauma: What you need to know." J Trauma Acute Care Surg 2025;100(4):532-541. PMID: 41417654